Skip to main content
Oryzon Genomics S.A. logo

Oryzon Genomics S.A. — Investor Relations & Filings

Ticker · ORY ISIN · ES0167733015 LEI · 95980063R15RDF29DK13 MC Manufacturing
Open in API
Filings indexed 142 across all filing types
Latest filing 2025-06-27 Declaration of Voting R…
Country ES Spain
Listing MC ORY

About Oryzon Genomics S.A.

https://www.oryzon.com/en

Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.

Recent filings

Filing Released Lang Actions
ORYZON anuncia los resultados de la votación de su Junta General Ordinaria de Accionistas
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document explicitly states that the 'Junta General Ordinaria de Accionistas 2025' (Annual General Meeting 2025) has taken place. It lists the resolutions approved, which include the approval of annual accounts (related to the 10-K/AR), the management report, and the annual remuneration report. Crucially, it concludes by stating that the adopted agreements and voting results will be made available on the company website, implying this document is the official announcement of the meeting's outcome rather than the full presentation materials or the detailed reports themselves. Since it details the results of the shareholder vote on various resolutions, the most fitting category is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it mentions AGM topics, the core content is the confirmation of the meeting's conclusion and the results of the votes.
2025-06-27 Spanish
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S.A.
AGM Information Classification · 98% confidence The document explicitly states it is a 'CONVOCATORIA DE LA JUNTA GENERAL ORDINARIA DE ACCIONISTAS 2025 DE ORYZON GENOMICS, S.A.' (Notice of the 2025 Annual General Shareholders' Meeting). It details the date, time, location, and the Order of the Day (ORDEN DEL DÍA), which includes approving annual accounts and management reports. This content directly relates to the formal process of calling and providing information for the Annual General Meeting (AGM). Although it mentions the AGM, the document itself is the official notice/material distributed to shareholders regarding the meeting, which aligns best with the 'AGM Information' category (AGM-R). It is not a DEF 14A (Remuneration Report) or a DVA (Declaration of Voting Results), as it precedes the meeting.
2025-05-26 Spanish
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S.A.
AGM Information Classification · 98% confidence The document explicitly states it is a 'CONVOCATORIA DE LA JUNTA GENERAL ORDINARIA DE ACCIONISTAS 2025 DE ORYZON GENOMICS, S.A.' (Notice of the 2025 Annual General Shareholders' Meeting). It details the date, time, location, and the Order of the Day (ORDEN DEL DÍA), which includes approving annual accounts and management reports. This content directly relates to the formal process of calling and providing information for the Annual General Meeting (AGM). Although it mentions the AGM, the document itself is the official notice/material distributed to shareholders regarding the meeting, which aligns best with the 'AGM Information' category (AGM-R). It is not a DEF 14A (Remuneration Report) or a DVA (Declaration of Voting Results), as it precedes the meeting.
2025-05-26 Spanish
La sociedad remite información sobre los resultados del primer trimestre de 2025
Earnings Release Classification · 99% confidence The document is an official communication from ORYZON GENOMICS, S.A. stating it is releasing information regarding its first quarter of 2025 results. The text explicitly mentions: "ORYZON remite nota de prensa en relación con los resultados correspondientes al primer trimestre de 2025, que se adjunta a la presente." (ORYZON sends a press release regarding the results corresponding to the first quarter of 2025, which is attached hereto.) and is titled "Oryzon anuncia sus resultados y avances en el primer trimestre de 2025". This structure—a brief announcement referencing an attached press release detailing period results—is characteristic of an Earnings Release (ER). Although the document is long (over 32,000 characters), the initial framing is an announcement of results, not the full, detailed regulatory filing (like a 10-K or IR). The content focuses on key financial highlights (R&D spend, net result, capital increase) and operational updates for the quarter, fitting the ER definition better than the comprehensive Interim Report (IR) or the full Annual Report (10-K). Q1 2025
2025-05-12 Spanish
ORYZON recibe una ayuda no reembolsable de 13,26 millones de € para su proyecto VANDAM dentro de Med4Cure, el primer proyecto IPCEI en el sector sanitario
Regulatory Filings Classification · 100% confidence The document is a formal communication from ORYZON GENOMICS, S.A. dated May 8, 2025, titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It announces the publication of a press release regarding the provisional resolution granting Oryzon non-reimbursable aid (€13.26 million) for the Med4Cure IPCEI project. The text explicitly states, 'Se adjunta la nota de prensa que será distribuida en el día de hoy' (The press release that will be distributed today is attached) and then proceeds to detail the content of that press release. Since the document's primary function is to announce the publication/release of another document (the press release/news about the funding) rather than being the full financial report (like 10-K or IR) or a transcript, it fits the definition of a Report Publication Announcement (RPA). The length (15,255 chars) is substantial, but the structure strongly suggests an official regulatory disclosure announcing the availability of key news, which aligns best with RPA or RNS. Given the specific nature of announcing the release of a press release/news item, RPA is the most precise fit over the general RNS fallback.
2025-05-08 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM". This form explicitly deals with transactions (share dealings) conducted by directors or senior management (PDMRs) of the issuer (ORYZON GENOMICS, S.A.). This directly corresponds to the definition of Director's Dealing (Insider Trades). The relevant filing code is DIRS.
2025-04-29 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.